#RNL2021 coverage from @DrPetryna Refractory RA by Dr. Buch: -active DZ after >2 b/ts DMARDs -why rfRA exists: ?Immunologic heterogeneity of RA ?contributing co-morbidities ?unidentified Rx target -effective Rx in early disease decreases risk of future rfRA" https://t.co/ecrbqlvemf